Sarepta Therapeutics Inc (SRPT): Sad Trombone?

The FDA could take a cautious stance and opt against an accelerated pathway for eteplirsen. Another experimental DMD drug — drisapersen from GlaxoSmithKline plc (ADR) (NYSE:GSK) — reportedly resulted in patients experiencing kidney toxicity. Last quarter, Garabedian alluded to possible FDA concerns about this safety issue, but he shrugged off any worries about eteplirsen producing similar effects.

However, the FDA could just as easily give the green light for an accelerated approval pathway for eteplirsen. While the number of patients involved in previous studies was small, the results were very positive and the need for some treatment for DMD patients is great.

Sarepta Therapeutics Inc (NASDAQ:SRPT)’s first-quarter results really are immaterial in the bigger scheme. What really matters is eteplirsen and how quickly it can get to market. Good news on that front would get Sarepta in full swing. Nothing else means a thing for now.

The article Sarepta’s Meaningless Q1 Results originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.